Journal of Gastric Cancer

  • 제23권2호
  • /
  • Pages.251-252
  • /
  • 2023
  • /
  • 2093-582X(pISSN)
  • /
  • 2093-5641(eISSN)
대한위암학회 (The Korean Gastric Cancer Association)
권호 표지
DOI QR코드

DOI QR Code

Clinical Implication of Liver Metastasis in the Treatment of Gastric Cancer

  • Chi Hoon Maeng (Division of Medical Oncology-Hematology, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University College of Medicine)
  • 투고 : 2023.04.20
  • 심사 : 2023.04.21
  • 발행 : 2023.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235. https://doi.org/10.1016/S1470-2045(14)70420-6
  2. Shitara K, Ikeda J, Kondo C, Takahari D, Ura T, Muro K, et al. Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer 2012;15:137-143. https://doi.org/10.1007/s10120-011-0083-8
  3. Wang S, Feng Y, Swinnen J, Oyen R, Li Y, Ni Y. Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study. Am J Cancer Res 2020;10:1477-1517.
  4. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-2403. https://doi.org/10.1200/JCO.2004.08.154
  5. Ogata T, Narita Y, Wainberg ZA, Van Cutsem E, Yamaguchi K, Piao Y, et al. Exploratory analysis of patients with gastric/gastroesophageal junction adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study. J Gastric Cancer 2023;23:289-302. https://doi.org/10.5230/jgc.2023.23.e15
  6. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16:499-508. https://doi.org/10.1016/S1470-2045(15)70127-0
  7. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382:2419-2430. https://doi.org/10.1056/NEJMoa2004413
  8. Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol 2023;41:1470-1491. https://doi.org/10.1200/JCO.22.02331
  9. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:1005-1020. https://doi.org/10.1016/j.annonc.2022.07.004